Company Profile

UCB SA (OTC: UCBJY)
8:50 PM UTC, 11/14/24
Last: $93.55 Change: -2.76 %Change: -2.87% Volume: 6,232
Detailed Quote
Open: $ 94.78   Volume: 6,232
High: $ 94.78   Yield(%) 0.48
Low: $ 93.55   P/E Ratio (ttm): 141.59
Dividend ($): 0.46   Market Cap ($): 36.71B
EPS ($) n/a   Shares Out: 379.44M
M = Million B = Billion
Price Performance
% Price Change (last 4 weeks): 3.87
% Price Change (last 13 weeks): 16.53
% Price Change (last 26 weeks): 45.42
% Price Change (last 52 weeks): 162.77
% Price Change (year to date): 121.99
Management Effectiveness
Return on Equity (%): 3.79
Return on Assets (%): 2.17
Return on Invested Capital (%): 7.02
Profitability
Gross Profit Margin (%): 63.63
Net Profit Margin (%): 6.53
Operating Profit Margin (%): 5.31
Price & Volume
50-day Moving Average: $93.21
200-day Moving Average: $74.88
Avg. Daily Vol. (last 50 days): 20,830
Avg. Daily Vol. (last 200 days): 19,305
52-wk high: $99.40
52-wk low: $36.35
Bid: $n/a
Ask: $n/a
Company Information
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
UCB SA
Allée de la Recherche, 60
Brussels BU 1070

Phone: 32.2.559.99.99
Fax: n/a
http://www.ucb.com
Per Share Data
Earnings (1year) ($): 0.68
Annual Dividend ($): 0.46
Current P/E Ratio (ttm): 141.59
Book Value ($): 26.12
Cash Flow ($): 2.95
Valuation Ratios
Price/Earnings (x): 141.59
Price/Sales (x): 3.00
Price/Book (x): 1.67
Price/Cash Flow (x): 25.50
Financial Strength
Quick Ratio (x): 0.92
Current Ratio (x): 1.32
LT Debt/Equity (x): 33.38
Total Debt/Equity (x): 33.85



Quotes displayed with 15 minutes delay. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. News provided by MT Newswires, a Division of MidnightTrader, Inc. Events Data provided by Wall Street Horizon. ©2021 Wall Street Horizon, Inc.